Literature DB >> 10845259

Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey.

R Manfredi1, A Nanetti, M Ferri, F Chiodo.   

Abstract

Two hundred and twenty-four episodes of Pseudomonas spp. complications that occurred in 179 consecutive patients with HIV infection were retrospectively reviewed. Pseudomonas spp. organisms were responsible for 11.6% of 1933 episodes of non-mycobacterial bacterial diseases (5.4% of 1072 episodes of sepsis), observed over an 8-year period; 20.7% of patients experienced disease relapses (45 episodes). These complications mostly involved lower airways (66 cases), urinary tract (53 episodes), and blood (34 cases), with Pseudomonas aeruginosa isolated in 161 episodes, and other Pseudomonas spp. in the remaining 63 cases. An advanced HIV disease was frequently present (as expressed by a prior diagnosis of AIDS, a low CD4+ lymphocyte count, and leukopenia-neutropenia). Indwelling intravascular and urinary catheters were often associated with bacteremia and urinary tract involvement, respectively. More than 60% of patients were given antibiotics and/or cotrimoxazole in the month preceding the onset of Pseudomonas spp. disease. Bacterial strains isolated from our HIV-infected patients showed a favorable sensitivity to piperacillin, ceftazidime, imipenem, amikacin, tobramycin, and ciprofloxacin. An adequate antimicrobial treatment led to clinical and microbiological cure in 73.2% of patients at the first episode, and in 22.3% more subjects after one or more relapses. A lethal outcome occurred in only eight patients of 179 (4.5%), suffering from a far advanced HIV disease; P. aeruginosa infection directly contributed to death in four cases (sepsis, and/or pneumonia). Nosocomial disease occurred in 46.4% of the 224 episodes, and was significantly related to a previous diagnosis of AIDS, concurrent neutropenia, the occurrence of sepsis or urinary tract infection, disease relapses, the involvement of non-aeruginosa Pseudomonas spp., and a lethal outcome, compared with community-acquired infection. Our experience (the largest reported to date) confirms that Pseudomonas spp. (including non-aeruginosa Pseudomonas spp. organisms) is responsible for remarkable morbidity and mortality among patients with HIV infection, and may pose relevant problems to clinicians and microbiologists involved in the care of HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845259     DOI: 10.1023/a:1007626410724

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  59 in total

Review 1.  AIDS and the urinary tract.

Authors:  S O'Regan; P Russo; N Lapointe; E Rousseau
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus.

Authors:  U Frank; F D Daschner; G Schulgen; J Mills
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

3.  Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d'Ivoire.

Authors:  A D Grant; G Djomand; P Smets; A Kadio; M Coulibaly; A Kakou; C Maurice; J P Whitaker; F Sylla-Koko; D Bonard; S Z Wiktor; R J Hayes; K M De Cock; A E Greenberg
Journal:  AIDS       Date:  1997-09       Impact factor: 4.177

4.  Xanthomonas maltophilia: an emerging pathogen in patients with HIV disease.

Authors:  R Manfredi; A Nanetti; M Ferri; F Chiodo
Journal:  Int J STD AIDS       Date:  1998-04       Impact factor: 1.359

5.  Breast abscess with lethal septicemia due to Pseudomonas aeruginosa in a patient with AIDS.

Authors:  B Roca; C Vilar; E V Pérez; A Sáez-Royuela; E Simón
Journal:  Presse Med       Date:  1996-05-18       Impact factor: 1.228

Review 6.  Bacteremia and respiratory involvement by Alcaligenes xylosoxidans in patients infected with the human immunodeficiency virus.

Authors:  R Manfredi; A Nanetti; M Ferri; F Chiodo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

7.  Estimation of the effect of neutropenia on rates of clinical bacteraemia in HIV-infected patients.

Authors:  J Caperna; R E Barber; J G Toerner; W C Mathews
Journal:  Epidemiol Infect       Date:  1998-02       Impact factor: 2.451

8.  Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: clinical presentation, bacteriology, and outcome.

Authors:  H M Krumholz; M A Sande; B Lo
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

9.  Sepsis-bacteraemia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalized for HIV infection.

Authors:  R Manfredi; P Costigliola; E Ricchi; F Chiodo
Journal:  Clin Ter       Date:  1993-10

10.  Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome.

Authors:  C J Fichtenbaum; W C Dunagan; W G Powderly
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-01-01
View more
  23 in total

1.  Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era.

Authors:  S H Allen; P Brennan-Benson; M Nelson; D Asboe; M Bower; B Azadian; B Gazzard; J Stebbing
Journal:  Postgrad Med J       Date:  2003-12       Impact factor: 2.401

2.  DNA binding: a novel function of Pseudomonas aeruginosa type IV pili.

Authors:  Erin J van Schaik; Carmen L Giltner; Gerald F Audette; David W Keizer; Daisy L Bautista; Carolyn M Slupsky; Brian D Sykes; Randall T Irvin
Journal:  J Bacteriol       Date:  2005-02       Impact factor: 3.490

3.  The ThiL enzyme is a valid antibacterial target essential for both thiamine biosynthesis and salvage pathways in Pseudomonas aeruginosa.

Authors:  Hyung Jun Kim; Hyunjung Lee; Yunmi Lee; Inhee Choi; Yoonae Ko; Sangchul Lee; Soojin Jang
Journal:  J Biol Chem       Date:  2020-05-13       Impact factor: 5.157

Review 4.  Biology of Pseudomonas stutzeri.

Authors:  Jorge Lalucat; Antoni Bennasar; Rafael Bosch; Elena García-Valdés; Norberto J Palleroni
Journal:  Microbiol Mol Biol Rev       Date:  2006-06       Impact factor: 11.056

5.  Identification of genes involved in swarming motility using a Pseudomonas aeruginosa PAO1 mini-Tn5-lux mutant library.

Authors:  Joerg Overhage; Shawn Lewenza; Alexandra K Marr; Robert E W Hancock
Journal:  J Bacteriol       Date:  2006-12-08       Impact factor: 3.490

6.  A Novel RNase 3/ECP Peptide for Pseudomonas aeruginosa Biofilm Eradication That Combines Antimicrobial, Lipopolysaccharide Binding, and Cell-Agglutinating Activities.

Authors:  David Pulido; Guillem Prats-Ejarque; Clara Villalba; Marcel Albacar; Juan J González-López; Marc Torrent; Mohammed Moussaoui; Ester Boix
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Pseudomonas aeruginosa AlgR controls cyanide production in an AlgZ-dependent manner.

Authors:  William L Cody; Christopher L Pritchett; Adriana K Jones; Alexander J Carterson; Debra Jackson; Anders Frisk; Matthew C Wolfgang; Michael J Schurr
Journal:  J Bacteriol       Date:  2009-03-06       Impact factor: 3.490

Review 8.  Evaluation of respiratory disease.

Authors:  Sofya Tokman; Laurence Huang
Journal:  Clin Chest Med       Date:  2013-04-15       Impact factor: 2.878

9.  Human host defense peptide LL-37 prevents bacterial biofilm formation.

Authors:  Joerg Overhage; Andrea Campisano; Manjeet Bains; Ellen C W Torfs; Bernd H A Rehm; Robert E W Hancock
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

10.  Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa.

Authors:  Vincenzo Luca; Annarita Stringaro; Marisa Colone; Alessandro Pini; Maria Luisa Mangoni
Journal:  Cell Mol Life Sci       Date:  2013-03-16       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.